Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05866536 · ClinicalTrials.gov registry record · Phase 2
Repeat BCG Vaccinations for the Treatment of New Onset Type 1 Diabetes in Children Age 8-<18 Years
A Phase 2 study of Diabetes Mellitus and Type 1 Diabetes, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT05866536 is a Phase 2 study of Diabetes Mellitus and Type 1 Diabetes that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 100 participants, below the 1,867-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05866536, a Phase 2 study of Diabetes Mellitus and Type 1 Diabetes, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to investigate if repeat bacillus Calmette-Guérin (BCG) vaccinations can confer a beneficial immune and metabolic effect in new onset pediatric Type 1 diabetes.
Conditions Studied
Interventions
- BIOLOGICAL Bacillus Calmette-Guérin
- BIOLOGICAL Saline Injection
Study Locations (1)
Massachusetts
- Immunobiology Labs CNY 149 - Charlestown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2023-05-04 |
| Est. Completion | 2028-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05866536
The ClinicalTrials.gov registry entry for NCT05866536 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,867-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (95% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Diabetes Mellitus appearing as the primary indexed condition, and to 2 interventions - of which Bacillus Calmette-Guérin is the first listed.
NCT05866536 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05866536 about?
NCT05866536 is a clinical study titled "Repeat BCG Vaccinations for the Treatment of New Onset Type 1 Diabetes in Children Age 8-<18 Years". The purpose of this study is to investigate if repeat bacillus Calmette-Guérin (BCG) vaccinations can confer a beneficial immune and metabolic effect in new onset pediatric Type 1 diabetes.
What is the current status of trial NCT05866536?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2023-05-04. Estimated completion is 2028-05.
What conditions does trial NCT05866536 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 1 Diabetes, Autoimmune Diabetes, Diabetes type1.
What interventions are being tested in trial NCT05866536?
The interventions under investigation include: Bacillus Calmette-Guérin (BIOLOGICAL), Saline Injection (BIOLOGICAL).
Who is sponsoring clinical trial NCT05866536?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05866536 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals
RECRUITING · Phase 2
-
Effects of Ondansetron on Gastrointestinal Sensorimotor Dysfunctions in Diabetes Mellitus and Dyspepsia
RECRUITING · Phase 2
-
Pioglitazone Versus Empagliflozin for Chronic Pancreatitis/Recurrent Acute Pancreatitis Associated Diabetes Mellitus
RECRUITING · Phase 2
-
Smart Walk: A Culturally Tailored Smartphone-Delivered Physical Activity Intervention for African American Women
RECRUITING · Phase 2
-
Sleep, Diabetic Retinopathy and Melatonin
RECRUITING · Phase 2
-
Safety, Tolerability, Pharmacokinetics,Pharmacodynamics Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.